Epiduo/Tactuo
Drugtopical to the face, once daily in the evening
NCT Number: NCT01474590
Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.
Looking for future studies?
Notify Me12 year–35 year
All sexes
Interventional
Phase 3
Galderma investigational site, Ajax, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
topical to the face, once daily in the evening
topical to the face, once daily in the evening
oral, 2 capsules once daily in the morning with aglass of water and with food
oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
Time frame: 20 weeks
Overall success is reached when the 2 following criteria are fulfilled :
Galderma R&D
Industry
Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne
Acronym: POWER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07572331
Acne, Acne Vulgaris
Beverly, Massachusetts, United States
View Trial DetailsNCT07076784
Acne, Acne Scars
Seoul, South Korea
View Trial DetailsNCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial DetailsNCT07428915
Acne, Acne Conglobata
Bilbao, Basque Country, Spain
View Trial Details